Cargando…
A Rare Pathological Phenotype of Endometrioid Serous and Clear-Cell Ovarian Cancer with PIK3CA Mutations in Relation to The Excellent Response of Alpelisib
Patients with metastatic ovarian cancer who develop resistance to standard therapy with or without platinum need to search for other therapeutic choices. Therefore, identifying genetic alterations and selecting an approach to treatment using precision medicine techniques are important. In a patient...
Autores principales: | Bayram, Ertugrul, Khatib, Ghanim, Guney, Burak, Kilicbagir, Emine, Gulec, Huru Rabia, Boga, Ibrahim, Paydas, Semra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454507/ https://www.ncbi.nlm.nih.gov/pubmed/37628682 http://dx.doi.org/10.3390/genes14081632 |
Ejemplares similares
-
Issues with the targeted therapy of non‑small cell lung cancer with thyroid metastases: A case report
por: Bayram, Ertugrul, et al.
Publicado: (2023) -
Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib
por: Morin, Gabriel, et al.
Publicado: (2022) -
Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression—A Case Report
por: Sheth, Hardik, et al.
Publicado: (2021) -
Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
por: Batalini, Felipe, et al.
Publicado: (2020) -
Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer
por: Wilhoit, Tori, et al.
Publicado: (2020)